IMPORTANT INFORMATION

This website is no longer being updated.

NHS Rotherham Clinical Commissioning Group has, from 1 July 2022, been replaced by the new NHS South Yorkshire Integrated Care Board (ICB). The ICB is now responsible for commissioning and funding of health and care services in the local area. Please go to our new website www.southyorkshire.icb.nhs.uk for information about the work of NHS South Yorkshire ICB.

For local health information visit Your Health Rotherham

To view an archive of this website, please click here

Thank you.

branch graphic

FOI Disclosure Log

Use the form below to search for FAQs containing specific words

Search for:
CCG 1341 Use of rituximab at NHS Rotherham CCG.

Request 1

Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications?

Response 1

The RCCG does not hold this information, however, you may wish to contact Rotherham Hospital Freedom of Information Department using the following email address:-freedomofinformation@rothgen.nhs.uk.  Please put Freedom of Information in the subject line.

 

Request 2

Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

*if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)

Response 2

Please see response 1.

 

Request 3

Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

 

*if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)

Response 3

Please see response 1.

 

Request 4

Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these?

Response 4

Please see response 1

Request 5

Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera?

Response 5

Please see response 1

Request 6

Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?

Response 6

Please see response 1.

 

Request 7

Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed?

Response 7

Please see response 1.

 

Request 8

Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

*if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)

 

Response 8

Please see response 1.

 

Request 9

As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings.

Response 9

Please see response 1.

 

Request 10

Please provide information on the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC):

*if the total contract value is not available, please provide the price range for each drug

 

Response 10

Please see response 1.

 

Request 11

Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers?

Response 11

Please see response 1.